

Francois Ghiringhelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5012640/publications.pdf>

Version: 2024-02-01

213
papers

36,054
citations

13099

68
h-index

3407

183
g-index

223
all docs

223
docs citations

223
times ranked

39985
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	12.6	3,689
2	Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. <i>Nature Medicine</i> , 2007, 13, 1050-1059.	30.7	2,657
3	Calreticulin exposure dictates the immunogenicity of cancer cell death. <i>Nature Medicine</i> , 2007, 13, 54-61.	30.7	2,580
4	Activation of the NLRP3 inflammasome in dendritic cells induces IL-1–dependent adaptive immunity against tumors. <i>Nature Medicine</i> , 2009, 15, 1170-1178.	30.7	1,614
5	The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide. <i>Science</i> , 2013, 342, 971-976.	12.6	1,580
6	Immunological aspects of cancer chemotherapy. <i>Nature Reviews Immunology</i> , 2008, 8, 59-73.	22.7	1,374
7	Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. <i>Journal of Experimental Medicine</i> , 2005, 202, 1691-1701.	8.5	1,224
8	Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice. <i>Science</i> , 2011, 334, 1573-1577.	12.6	1,159
9	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 641-648.	4.2	1,104
10	5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity. <i>Cancer Research</i> , 2010, 70, 3052-3061.	0.9	1,098
11	CD4 ⁺ CD25 ⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. <i>European Journal of Immunology</i> , 2004, 34, 336-344.	2.9	846
12	CD4 ⁺ CD25 ⁺ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–dependent manner. <i>Journal of Experimental Medicine</i> , 2005, 202, 1075-1085.	8.5	806
13	Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2010, 120, 457-71.	8.2	761
14	Consensus guidelines for the detection of immunogenic cell death. <i>Oncotarget</i> , 2014, 3, e955691.	4.6	686
15	Tumor cells convert immature myeloid dendritic cells into TGF–secreting cells inducing CD4+CD25+ regulatory T cell proliferation. <i>Journal of Experimental Medicine</i> , 2005, 202, 919-929.	8.5	676
16	Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. <i>Nature Medicine</i> , 2013, 19, 57-64.	30.7	634
17	The anticancer immune response: indispensable for therapeutic success?. <i>Journal of Clinical Investigation</i> , 2008, 118, 1991-2001.	8.2	520
18	The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. <i>Immunological Reviews</i> , 2007, 220, 47-59.	6.0	491

#	ARTICLE	IF	CITATIONS
19	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	1.8	395
20	A novel dendritic cell subset involved in tumor immunosurveillance. <i>Nature Medicine</i> , 2006, 12, 214-219.	30.7	377
21	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. <i>Science</i> , 2012, 337, 1678-1684.	12.6	367
22	Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death. <i>Science Translational Medicine</i> , 2012, 4, 143ra99.	12.4	367
23	Contribution of IL-17 ⁺ producing $\hat{I}^3\hat{I}$ T cells to the efficacy of anticancer chemotherapy. <i>Journal of Experimental Medicine</i> , 2011, 208, 491-503.	8.5	303
24	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas. <i>JAMA Oncology</i> , 2018, 4, 93.	7.1	303
25	Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 909-918.	4.2	280
26	Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells. <i>Clinical Cancer Research</i> , 2008, 14, 2413-2420.	7.0	277
27	Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression. <i>Immunity</i> , 2012, 36, 362-373.	14.3	275
28	Immunogenic cancer cell death: a key-lock paradigm. <i>Current Opinion in Immunology</i> , 2008, 20, 504-511.	5.5	271
29	The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. <i>Immunological Reviews</i> , 2006, 214, 229-238.	6.0	235
30	Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance. <i>Nature Communications</i> , 2018, 9, 322.	12.8	226
31	Intestinal <i>Akkermansia muciniphila</i> predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. <i>Nature Medicine</i> , 2022, 28, 315-324.	30.7	225
32	Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. <i>Annals of Oncology</i> , 2015, 26, 1813-1823.	1.2	219
33	Cross-reactivity between tumor MHC class I ⁺ restricted antigens and an enterococcal bacteriophage. <i>Science</i> , 2020, 369, 936-942.	12.6	217
34	Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1627-1634.	4.2	207
35	<i>In situ</i> immune response after neoadjuvant chemotherapy for breast cancer predicts survival. <i>Journal of Pathology</i> , 2011, 224, 389-400.	4.5	204
36	Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX ⁺ Bevacizumab Drug Treatment Regimen. <i>Cancer Research</i> , 2016, 76, 5241-5252.	0.9	203

#	ARTICLE	IF	CITATIONS
37	Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. <i>Gut</i> , 2010, 59, 341-347.	12.1	195
38	Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines. <i>Journal of Immunology</i> , 2006, 176, 2722-2729.	0.8	192
39	The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. <i>Nature Immunology</i> , 2014, 15, 758-766.	14.5	187
40	Chemotherapy and radiotherapy: Cryptic anticancer vaccines. <i>Seminars in Immunology</i> , 2010, 22, 113-124.	5.6	183
41	PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1433981.	4.6	167
42	STAT3 activation. <i>Jak-stat</i> , 2013, 2, e23010.	2.2	159
43	Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv330.	6.3	159
44	Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3157-3165.	1.6	149
45	Interleukin-1 β and Cancer. <i>Cancers</i> , 2020, 12, 1791.	3.7	146
46	Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. <i>Oncolmmunology</i> , 2016, 5, e1054598.	4.6	144
47	Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. <i>European Journal of Cancer</i> , 2020, 131, 40-50.	2.8	143
48	Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1579-1587.	4.2	137
49	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2018, 119, 950-960.	6.4	133
50	Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. , 2019, 7, 160.		132
51	Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. <i>Oncolmmunology</i> , 2019, 8, e1564505.	4.6	118
52	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. <i>Nature Medicine</i> , 2020, 26, 919-931.	30.7	118
53	Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 65-72.	2.5	115
54	What Is the Role of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?. <i>Oncologist</i> , 2009, 14, 848-861.	3.7	109

#	ARTICLE	IF	CITATIONS
55	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1094-1106.	10.7	108
56	CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?. <i>Clinical Cancer Research</i> , 2008, 14, 5242-5249.	7.0	104
57	Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation. <i>Cell Reports</i> , 2017, 19, 746-759.	6.4	104
58	Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells. <i>PLoS ONE</i> , 2013, 8, e65181.	2.5	103
59	Cathepsin B Is Required for NLRP3 Inflammasome Activation in Macrophages, Through NLRP3 Interaction. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 167.	3.7	103
60	Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. <i>Gut</i> , 2020, 69, 531-539.	12.1	97
61	Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , 2015, 11, 1878-1890.	9.1	91
62	The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , 2016, 12, 864-875.	9.1	90
63	Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor Immunoescape. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-9.	3.0	87
64	Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. <i>Cancer Immunology Research</i> , 2019, 7, 1958-1969.	3.4	87
65	<i>Helicobacter pylori</i> infection has a detrimental impact on the efficacy of cancer immunotherapies. <i>Gut</i> , 2022, 71, 457-466.	12.1	87
66	A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota. <i>Cancer Discovery</i> , 2022, 12, 1070-1087.	9.4	86
67	Antibiotic Use Does Not Appear to Influence Response to Nivolumab. <i>Anticancer Research</i> , 2017, 37, 3195-3200.	1.1	83
68	HSP70 is a negative regulator of NLRP3 inflammasome activation. <i>Cell Death and Disease</i> , 2019, 10, 256.	6.3	81
69	Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. <i>Gut</i> , 2020, 69, 681-690.	12.1	79
70	MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. <i>Cancer Cell</i> , 2022, 40, 136-152.e12.	16.8	79
71	Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodiges-14 Trial. <i>Cells</i> , 2019, 8, 516.	4.1	78
72	Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 852-873.	1.7	76

#	ARTICLE	IF	CITATIONS
73	Controversies on the role of Th17 in cancer: a TGF- β -dependent immunosuppressive activity?. Trends in Molecular Medicine, 2012, 18, 742-749.	6.7	75
74	Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth. Journal of Investigative Dermatology, 2013, 133, 499-508.	0.7	75
75	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. Gastric Cancer, 2020, 23, 73-81.	5.3	75
76	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death and Differentiation, 2021, 28, 2778-2796.	11.2	72
77	Desirable cell death during anticancer chemotherapy. Annals of the New York Academy of Sciences, 2010, 1209, 99-108.	3.8	70
78	High Pressure Enhances the Effect of Hyperthermia in Intraperitoneal Chemotherapy With Oxaliplatin. Annals of Surgery, 2012, 256, 1084-1088.	4.2	70
79	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). Journal of Clinical Oncology, 2018, 36, 674-681.	1.6	70
80	Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. Journal of Molecular Medicine, 2007, 85, 1069-1076.	3.9	68
81	STAT3, a Master Regulator of Anti-Tumor Immune Response. Cancers, 2019, 11, 1280.	3.7	68
82	Selective degradation of PU.1 during autophagy represses the differentiation and antitumour activity of TH9 cells. Nature Communications, 2017, 8, 559.	12.8	67
83	TH9 cells in anti-tumor immunity. Seminars in Immunopathology, 2017, 39, 39-46.	6.1	63
84	Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study. OncoImmunology, 2018, 7, e1474319.	4.6	63
85	Follicular helper-T cells restore CD8 ⁺ -dependent antitumor immunity and anti-PD-L1/PD-1 efficacy. , 2021, 9, e002157.		63
86	CD4 ⁺ CD25 ⁺ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. Journal of Clinical Investigation, 2008, 118, 3751-3761.	8.2	56
87	Th9 Cells: A Novel CD4 T-cell Subset in the Immune War against Cancer. Cancer Research, 2015, 75, 475-479.	0.9	56
88	Platinum Derivatives Effects on Anticancer Immune Response. Biomolecules, 2020, 10, 13.	4.0	55
89	Harnessing dendritic cells in cancer. Seminars in Immunology, 2011, 23, 42-49.	5.6	53
90	Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?. Frontiers in Immunology, 2019, 10, 1816.	4.8	52

#	ARTICLE	IF	CITATIONS
91	SOCS3 Transactivation by PPAR β Prevents IL-17-Driven Cancer Growth. <i>Cancer Research</i> , 2013, 73, 3578-3590.	0.9	51
92	Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein <sc>TRF</sc>. <i>EMBO Journal</i> , 2019, 38, .	7.8	49
93	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancers</i> , 2019, 11, 201.	3.7	49
94	The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 19-30.	3.0	48
95	Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. <i>Journal of Neuro-Oncology</i> , 2012, 107, 351-358.	2.9	47
96	Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses. <i>Nature Immunology</i> , 2022, 23, 262-274.	14.5	47
97	Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: A French population-based study. <i>Digestive and Liver Disease</i> , 2014, 46, 854-858.	0.9	46
98	Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?. <i>Future Oncology</i> , 2015, 11, 2645-2654.	2.4	44
99	5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. <i>Oncotarget</i> , 2018, 9, 11559-11571.	1.8	44
100	IRF8-dependent molecular complexes control the Th9 transcriptional program. <i>Nature Communications</i> , 2017, 8, 2085.	12.8	43
101	Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000375.	4.5	43
102	Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma. <i>Oncotarget</i> , 2016, 7, 70948-70958.	1.8	43
103	Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: A pooled analysis of two randomised trials. <i>European Journal of Cancer</i> , 2014, 50, 506-516.	2.8	41
104	Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy. <i>Cancers</i> , 2020, 12, 2637.	3.7	40
105	Human ectonucleotidase-expressing CD25 ^{high} Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. <i>Oncolmmunology</i> , 2016, 5, e1055444.	4.6	39
106	Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 957-966.	7.0	37
107	Cell-Death-Associated Molecular Patterns As Determinants of Cancer Immunogenicity. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1098-1116.	5.4	36
108	Immune effects of 5-fluorouracil. <i>Oncolmmunology</i> , 2013, 2, e23139.	4.6	35

#	ARTICLE	IF	CITATIONS
109	Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1 β secretion in 5-fluorouracil-treated MDSC: implication in cancer treatment. <i>Cell Death and Disease</i> , 2019, 10, 485.	6.3	34
110	Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. <i>Anticancer Research</i> , 2010, 30, 4317-23.	1.1	34
111	FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. <i>Annals of Oncology</i> , 2012, 23, 2552-2561.	1.2	31
112	Role of myeloid-derived suppressor cells in tumor immunotherapy. <i>Immunotherapy</i> , 2012, 4, 43-57.	2.0	31
113	RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer. , 2018, 6, 123.		31
114	Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?. <i>Oncotarget</i> , 2016, 7, 9309-9321.	1.8	30
115	High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin. <i>Surgery</i> , 2015, 157, 72-78.	1.9	29
116	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. <i>European Journal of Cancer</i> , 2019, 115, 97-106.	2.8	29
117	Implementation and use of whole exome sequencing for metastatic solid cancer. <i>EBioMedicine</i> , 2020, 51, 102624.	6.1	29
118	Targeting BRAF and RAS in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 2201.	3.7	29
119	Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable, previously untreated metastatic colorectal cancer (MCRC): Results of the first intermediate analysis of the phase Ib/II MEDETREME trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3006-3006.	1.6	28
120	Effects of polyphenols and lipids from Pennisetum glaucum grains on T-cell activation: modulation of Ca ²⁺ and ERK1/ERK2 signaling. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 426.	3.7	27
121	Liver X Receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXR β subcellular localization. <i>Oncotarget</i> , 2015, 6, 26651-26662.	1.8	27
122	Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era. <i>Cells</i> , 2022, 11, 770.	4.1	26
123	Tumor Exosome-Mediated MDSC Activation. <i>American Journal of Pathology</i> , 2011, 178, 1403-1405.	3.8	25
124	Immune Th17 lymphocytes play a critical role in the multiple beneficial properties of resveratrol. <i>Food and Chemical Toxicology</i> , 2020, 137, 111091.	3.6	25
125	Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2549-2563.	4.2	24
126	Bevacizumab Efficacy in Metastatic Colorectal Cancer is Dependent on Primary Tumor Resection. <i>Annals of Surgical Oncology</i> , 2014, 21, 1632-1640.	1.5	23

#	ARTICLE	IF	CITATIONS
127	Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murin model of peritoneal carcinomatosis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 4.	8.6	22
128	Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 1565.	3.3	22
129	Immune classifications with cytotoxic CD8 ⁺ and Th17 infiltrates are predictors of clinical prognosis in glioblastoma. <i>Oncolmmunology</i> , 2017, 6, e1321186.	4.6	21
130	The role of telomeres in predicting individual radiosensitivity of patients with cancer in the era of personalized radiotherapy. <i>Cancer Treatment Reviews</i> , 2015, 41, 354-360.	7.7	20
131	Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years. <i>European Journal of Cancer</i> , 2019, 111, 116-125.	2.8	20
132	Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. <i>Investigational New Drugs</i> , 2012, 30, 758-764.	2.6	19
133	Peroxisome proliferator-activated receptor alpha deficiency impairs regulatory T cell functions: Possible application in the inhibition of melanoma tumor growth in mice. <i>Biochimie</i> , 2016, 131, 1-10.	2.6	18
134	Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study. <i>Anti-Cancer Drugs</i> , 2010, 21, 656-661.	1.4	17
135	Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2357-2363.	2.5	17
136	Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy. <i>Cancers</i> , 2020, 12, 2418.	3.7	17
137	FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study "Prodige 14" "ACCORD 21 (METHEP-2), a unicancer GI trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3512-3512.	1.6	17
138	Cell lines and immune classification of glioblastoma define patient's prognosis. <i>British Journal of Cancer</i> , 2019, 120, 806-814.	6.4	16
139	Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study. <i>European Journal of Cancer</i> , 2021, 148, 359-370.	2.8	16
140	Dacarbazine mediates antimelanoma effects via NK cells. <i>Oncolmmunology</i> , 2013, 2, e23714.	4.6	15
141	FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer. <i>Oncology</i> , 2014, 87, 148-158.	1.9	15
142	Induction of pyroptosis in colon cancer cells by LXR ² . <i>Molecular and Cellular Oncology</i> , 2015, 2, e970094.	0.7	15
143	Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers. <i>Oncolmmunology</i> , 2020, 9, 1836766.	4.6	15
144	Heat shock and HSP70 regulate 5-FU-mediated caspase-1 activation in myeloid-derived suppressor cells and tumor growth in mice. , 2020, 8, e000478.		15

#	ARTICLE	IF	CITATIONS
145	Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. <i>British Journal of Cancer</i> , 2022, 126, 1264-1270.	6.4	15
146	Prospective Study of the Evolution of Blood Lymphoid Immune Parameters during Dacarbazine Chemotherapy in Metastatic and Locally Advanced Melanoma Patients. <i>PLoS ONE</i> , 2014, 9, e105907.	2.5	14
147	The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas. <i>Journal of Hematology and Oncology</i> , 2015, 8, 52.	17.0	14
148	Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors. <i>Anticancer Research</i> , 2018, 38, 5963-5968.	1.1	14
149	Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France. <i>Journal of Geriatric Oncology</i> , 2020, 11, 802-806.	1.0	14
150	FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9 " FCD 0802). <i>Digestive and Liver Disease</i> , 2015, 47, 271-272.	0.9	13
151	Immunological features of coronavirus disease 2019 in patients with cancer. <i>European Journal of Cancer</i> , 2020, 139, 70-80.	2.8	13
152	Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES images. <i>Scientific Reports</i> , 2021, 11, 23912.	3.3	13
153	Transcriptional Programs Underlying Cd4 T Cell Differentiation and Functions. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 1-61.	3.2	12
154	Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency. <i>Cancers</i> , 2020, 12, 3550.	3.7	12
155	A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors. <i>Oncologist</i> , 2021, 26, e2254-e2264.	3.7	12
156	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. <i>Oncolimmunology</i> , 2016, 5, e1160193.	4.6	11
157	Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure. <i>Pharmaceuticals</i> , 2020, 13, 416.	3.8	11
158	Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients. <i>Cell Death and Differentiation</i> , 2021, 28, 1532-1547.	11.2	11
159	Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3020.	3.7	11
160	Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies. <i>Future Oncology</i> , 2013, 9, 469-472.	2.4	11
161	MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. , 2022, 10, e004241.		11
162	LPCAT2 controls chemoresistance in colorectal cancer. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1448245.	0.7	10

#	ARTICLE	IF	CITATIONS
163	Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer. <i>European Journal of Cancer</i> , 2019, 120, 97-106.	2.8	10
164	Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer. <i>Cells</i> , 2020, 9, 2071.	4.1	10
165	Red Wine Extract Disrupts Th17 Lymphocyte Differentiation in a Colorectal Cancer Context. <i>Molecular Nutrition and Food Research</i> , 2020, 64, 1901286.	3.3	10
166	Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1. <i>Oncolmmunology</i> , 2021, 10, 1957603.	4.6	10
167	Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma. <i>Oncotarget</i> , 2018, 9, 25617-25629.	1.8	10
168	Degarelix as a new antiangiogenic agent for metastatic colon cancer?. <i>World Journal of Gastroenterology</i> , 2013, 19, 769.	3.3	10
169	Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2699-2707.	2.5	9
170	Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience. <i>Diagnostics</i> , 2021, 11, 122.	2.6	9
171	Immunodynamics of explanted human tumors for immuno-oncology. <i>EMBO Molecular Medicine</i> , 2021, 13, e12850.	6.9	9
172	FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2018, 9, 110-118.	2.3	9
173	Socs3 induction by PPAR γ 3 restrains cancer-promoting inflammation. <i>Cell Cycle</i> , 2013, 12, 2157-2158.	2.6	8
174	Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 141-150.	2.3	8
175	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. <i>Oncolmmunology</i> , 2017, 6, e1339856.	4.6	8
176	HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1245-1246.	2.2	7
177	Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. <i>Cancers</i> , 2020, 12, 1429.	3.7	7
178	Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2019, 10, 75-85.	2.3	7
179	Can the hyperthermia-mediated heat shock factor/heat shock protein 70 pathway dampen the cytokine storm during SARS-CoV-2 infection?. <i>British Journal of Pharmacology</i> , 2022, 179, 4910-4916.	5.4	6
180	TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer. <i>Cancers</i> , 2021, 13, 4394.	3.7	6

#	ARTICLE	IF	CITATIONS
181	Isolated Lung Perfusion as an Adjuvant Treatment of Colorectal Cancer Lung Metastases: A Preclinical Study in a Pig Model. <i>PLoS ONE</i> , 2013, 8, e59485.	2.5	6
182	Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients. <i>Cancers</i> , 2021, 13, 5562.	3.7	6
183	Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases. <i>Medical Oncology</i> , 2010, 27, 938-941.	2.5	5
184	Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2015, 33, 1263-1266.	2.6	5
185	Development of a novel highly anti-proliferative family of gold complexes: Au(κ^2 -phosphonium-phosphines). <i>Dalton Transactions</i> , 2021, 50, 4880-4889.	3.3	5
186	New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases. <i>Frontiers in Immunology</i> , 2021, 12, 750407.	4.8	5
187	Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer. <i>European Journal of Cancer</i> , 2022, 172, 221-230.	2.8	5
188	Feasibility and Safety of Weekly Sequential Epirubicin-Paclitaxel as Adjuvant Treatment for Operable Breast Cancer Patients Older than 70 Years. <i>Clinical Breast Cancer</i> , 2011, 11, 235-240.	2.4	4
189	Immune ambivalence. <i>Oncolmmunology</i> , 2013, 2, e25737.	4.6	4
190	Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 48, 228-235.	1.4	4
191	Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX. <i>Anticancer Research</i> , 2020, 40, 4011-4015.	1.1	4
192	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020, 122, 957-962.	6.4	4
193	Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer. , 2021, 9, e002036.		4
194	ILC2s in cancer: context matters. <i>Nature Immunology</i> , 2021, 22, 804-806.	14.5	4
195	Mitophagy: a new actor in the efficacy of chemo-immunotherapy. <i>Autophagy</i> , 2022, 18, 3033-3034.	9.1	4
196	Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy. <i>International Journal of Cancer</i> , 2019, 145, 3101-3111.	5.1	3
197	Percutaneous Implantation of a Microcatheter-Port System for Hepatic Arterial Infusion Chemotherapy of Unresectable Liver Tumors: Technical Feasibility, Functionality, and Complications. <i>Diagnostics</i> , 2021, 11, 399.	2.6	3
198	Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. <i>World Journal of Gastroenterology</i> , 2009, 15, 4278.	3.3	3

#	ARTICLE	IF	CITATIONS
199	Parallel Evolution and Differences in Seroprevalence of SARS-CoV-2 Antibody Between Cancer Patients and Health Care Workers in a Tertiary Cancer Center During First and Second Wave of COVID-19 Pandemic: canSEROcov-II Cross Sectional Study. <i>European Journal of Cancer</i> , 2022, 165, 13-24.	2.8	3
200	Conception and Evaluation of Fluorescent Phosphine-Gold Complexes: From Synthesis to in vivo Investigations. <i>ChemMedChem</i> , 2022, , .	3.2	3
201	Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice. <i>Cancers</i> , 2022, 14, 1675.	3.7	3
202	Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma. <i>Cancers</i> , 2021, 13, 1851.	3.7	2
203	Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 634-641.	2.0	2
204	Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects. <i>Cancer Immunology Research</i> , 2022, 10, 900-916.	3.4	2
205	GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non-small cell lung cancer (NSCLC) A randomized, double-blind trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9152-TPS9152.	1.6	2
206	Utility of exome sequencing in routine care for metastatic colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2021, 15, 229.	1.0	1
207	Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?. <i>Lung Cancer</i> , 2021, 161, 98-107.	2.0	1
208	Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3343.	4.1	1
209	Transcription Factor Binding Studies in CD4+ T Cells: siRNA Transfection, Chromatin Immunoprecipitation, and Liquid Luminescent DNA Precipitation Assay. <i>Methods in Molecular Biology</i> , 2017, 1585, 167-177.	0.9	0
210	Effect of Pharmaceutical Compounds on Myeloid-Derived Suppressor Cells. , 2018, , 199-213.		0
211	Hype and hope of hepatic arterial infusion for colorectal cancer. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 235-237.	1.5	0
212	Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 5472.	3.7	0
213	MAPK signaling regulates the efficacy of chemoimmunotherapy. <i>Molecular and Cellular Oncology</i> , 2022, 9, 2054652.	0.7	0